技术辅助的解决方案聚焦干预(DIALOG+)治疗慢性抑郁症患者的临床与成本效果:多中心整群随机对照试验研究方案(TACK)
本研究为多中心整群随机对照试验方案,旨在评估DIALOG+对慢性抑郁症患者的临床与成本效果。计划招募约112名临床医生整群、共376例患者,按1:1随机分为DIALOG+组与常规治疗加DIALOG量表评估的活性对照组,干预期12个月,主要结局为12个月时主观生活质量。
要点
- DIALOG+是基于解决方案聚焦治疗原则的技术辅助干预,非诊断特异性,可灵活应用。
- 纳入标准包括抑郁症状或非精神病性心境低落至少2年、与临床医生有规律接触、主观生活质量低且抑郁症状中度。
- 主要结局为随机化后12个月时的主观生活质量,并在基线及3、6、12个月评估临床与社会结局及成本。
核心结论
- 该确定性多中心整群随机对照试验旨在评估DIALOG+对慢性抑郁症患者的临床与成本效果。
- 若在该患者人群中显示有效,DIALOG+可在大规模上改善精神卫生保健结局,使复杂共病患者受益。
研究设计与样本
- 多中心整群随机对照试验,为适应并检验DIALOG+用于慢性抑郁症的研究项目的一部分。
- 从英格兰国民健康服务体系(NHS England)多个站点招募常规接诊合格患者的临床医生,每个临床医生整群纳入1至6例患者。
- 整群按1:1比例随机分配至干预组(DIALOG+)或活性对照组(常规治疗加DIALOG量表)。
- 干预组临床医生接受培训并被要求定期实施干预12个月;活性对照组接受常规治疗,并在临床会谈结束时用DIALOG量表对生活领域和治疗满意度进行评分。
- 计划招募约112个临床医生整群,以达到总患者样本量376例。
关键数值与推荐
- 患者纳入标准:抑郁症状或非精神病性心境低落至少2年、与临床医生有规律接触、主观生活质量低且抑郁症状中度。
- 主要结局为随机化后12个月时的主观生活质量。
- 临床与社会结局(包括成本)在基线及随机化后3、6、12个月评估。
- 试验注册号ISRCTN11301686,注册日期2019年6月13日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many with an acute depressive disorder go on to develop chronic depression, despite ongoing care. There are few specifically designed interventions to treat chronic depression. DIALOG+, a technology-assisted intervention based on the principles of solution-focused therapy, may be beneficial. It has been shown to be effective as a treatment for patients with psychotic disorders, especially in regards to increasing quality of life. DIALOG+ was designed to be flexibly applied and not diagnosis-specific, aiming to structure communication and generate a personally-tailored care plan. This cluster randomised controlled trial (RCT) is part of a programme of research to adapt and test DIALOG+ for patients with chronic depression. METHODS: Patients will be eligible for the trial, if they have exhibited symptoms of depression or non-psychotic low mood for at least 2 years, have regular contact with a clinician and have a low subjective quality of life and moderate depressive symptoms. Clinicians, who routinely see eligible patients, will be recruited from a number of sites across NHS England. Clusters will have between 1 and 6 patients per clinician and will be randomised in a 1:1 ratio to either the intervention (DIALOG+) or active control group (treatment as usual + DIALOG scale). Clinicians in the intervention group are trained and asked to deliver the intervention regularly for 12 months. Active control participants receive treatment as usual and are asked to rate their satisfaction with areas of life and treatment on the DIALOG scale at the end of the clinical session. Approximately 112 clinician clusters will be recruited to reach a total patient sample size of 376. Clinical and social outcomes including costs are assessed at baseline and 3, 6 and 12 months post randomisation. The primary outcome will be subjective quality of life at 12 months. DISCUSSION: This definitive multi-site, cluster RCT aims to evaluate the clinical- and cost-effectiveness of DIALOG+ for people with chronic depression. If shown to be effective for this patient population it could be used to improve outcomes of mental health care on a larger scale, ensuring that patients with complex and co-morbid diagnoses can benefit. TRIAL REGISTRATION: ISRCTN11301686 . Registered on 13 Jun 2019.
引用
- McNamee P, Matanov A, Jerome L, et al. Clinical- and cost-effectiveness of a technology-supported and solution-focused intervention (DIALOG+) in treatment of patients with chronic depression-study protocol for a multi-site, cluster randomised controlled trial [TACK]. Trials. 2022. PMID: 35346348. doi:10.1186/s13063-022-06181-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。